Invesco NASDAQ Biotech UCITS ETF (LON:SBIO)
London
· Delayed Price · Currency is GBP · Price in USD | Assets | 245.03M |
| Expense Ratio | 0.40% |
| PE Ratio | 19.83 |
| Dividend (ttm) | n/a |
| Dividend Yield | n/a |
| Ex-Dividend Date | n/a |
| Payout Frequency | n/a |
| Payout Ratio | n/a |
| 1-Year Return | -0.82% |
| Volume | 57,302 |
| Open | 42.68 |
| Previous Close | 42.81 |
| Day's Range | 42.50 - 43.16 |
| 52-Week Low | 37.32 |
| 52-Week High | 51.36 |
| Beta | 0.82 |
| Holdings | 1 |
| Inception Date | Nov 6, 2014 |
About SBIO
Invesco NASDAQ Biotech UCITS ETF is an exchange traded fund launched by Source Investment Management Limited. The fund is managed by Assenagon Asset Management S.A. It invests in the public equity markets across the globe. The fund uses derivatives such as swaps to invest in the stocks of companies operating in the biotechnology and pharmaceuticals sectors. It invests in the stocks of companies across all market capitalizations, with a minimum market capitalization of US $200 million. The fund seeks to replicate the performance of the NASDAQ Biotechnology Index, by employing synthetic replication methodology. Invesco NASDAQ Biotech UCITS ETF was formed on November 6, 2014 and is domiciled in Ireland.
Performance
SBIO had a total return of -0.82% in the past year, including dividends. Since the fund's inception, the average annual return has been 3.18%.